Arvelle Therapeutics
Founded in 2019, Arvelle Therapeutics is a company that specializes in the development and commercialization of carbamate, an investigational anti-seizure medication. Arvelle Therapeutics is located in Switzerland.
Last updated on
About Arvelle Therapeutics
Estimated Revenue
$10M-$50MEmployees
51-250Funding / Mkt. Cap
$208MCategory
Sector
Health CareIndustry Group
Pharmaceuticals, Biotechnology & Life SciencesIndustry
PharmaceuticalsSIC Code
28NAICs Code
32541Location
City
ZugState
ZugCountry
SwitzerlandArvelle Therapeutics
Find your buyer within Arvelle Therapeutics